Switching to Aflibercept 8 mg for wet AMD
Treatments studied
Part of Eyes & vision clinical trials.
This trial tests if switching to a higher dose of aflibercept (Eylea) can help people with wet age-related macular degeneration (AMD) who need frequent eye injections. If you've been on other anti-VEGF injections for over a year and still need them more often than every 12 weeks, this study might offer a new option.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older with wet (neovascular) age-related macular degeneration.
- You have been treated with eye injections (anti-VEGF drugs) for more than one year.
- You switched to aflibercept 8 mg before July 31, 2025.
- Before switching, you needed injections less than 12 weeks apart.
- You do not have severe nearsightedness, certain eye diseases, or diabetic eye problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a biosimilar version of aflibercept (a drug that blocks abnormal blood vessel growth) in people with wet age-related macular degeneration. It aims to see how well the treatment works in real life.
This study looks at people with wet AMD who have been getting regular eye injections of either aflibercept or ranibizumab for over a year. The goal is to see what happens when they switch to a newer injection called faricimab.
This trial tests switching to a higher dose of aflibercept for people with wet age-related macular degeneration (AMD) who have already had several standard doses. It aims to see if a higher dose works better at keeping vision stable and reducing treatments.
This study tests a higher dose of the medicine aflibercept (brand name Eylea) in people who have already had at least three eye injections for wet age-related macular degeneration or diabetic macular edema. The goal is to see how well this stronger dose works in real-life conditions and how long its effects last.
This trial tests a higher dose of aflibercept given on a flexible schedule for people who have not yet been treated for wet age-related macular degeneration (nAMD). It aims to see if this approach is safe and effective at improving vision.
This study follows patients receiving aflibercept 8 mg injections in the eye to treat wet age-related macular degeneration (nAMD), a condition that blurs central vision. The goal is to understand how well this treatment works and its safety in routine medical practice.
Hear when a new Exudative Age-Related Macular Degeneration trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.